Skip to main content
Premium Trial:

Request an Annual Quote

J&J Joins BioWisdom's Tox Safety Program

NEW YORK (GenomeWeb News) - Johnson & Johnson Pharmaceutical Research & Development will use BioWisdom’s toxicity safety software in drug development programs, BioWisdom said today.
 
Under the three-year agreement, J&J has joined BioWisdom’s Safety Intelligence Program, which uses the company’s Sofia platform to create a “specialist medical search system” for drug safety risk assessment, BioWisdom said.
 
The SIP initiative is aimed at helping drug developers avoid drug-induced adverse events, BioWisdom said.
 
J&J is BioWisdom’s second SIP partner, following AstraZeneca, who joined the program last year.
 
Financial terms of the agreement were not released.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.